Invariant NKT Cell Ligands for Prostate Cancer Vaccines
Abstract
Invariant natural killer T cells (iNKT cells), through their ability to mature dendritic cells (DCs) and provide help for CD4 and CD8 T cell responses, can play a major role in regulation of the cellular adaptive immune response. Our major objective in this proposal is to identify an optimal agent and method of delivery for iNKT cell activation and enhancement of cytolytic T cell responses against prostate/PCa associated antigens. Our findings with respect to peptide based vaccines are not yet conclusive due largely to modest and inconsistent responses to peptides. It is well established that peptides (alone or pulsed onto DCs) are not optimal immunogens, and it is not yet clear whether or to what extent we can boost their efficacy using iNKT cell ligands. Over the next year we will assess some alternate approaches including the use of longer or modified peptides and other modes of administration, as the use of peptide or peptide pools still offers substantial advantages with respect to human clinical trials. In contrast to peptides, the data indicate that iNKT cell ligands can enhance responses to cellular vaccines. Therefore, in parallel with the peptide efforts, we will use this approach to assess alternative iNKT cell ligands and begin to assess efficacy in tumor bearing mice.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jun 01, 2011
- Accession Number
- ADA552889
Entities
People
- Steven P Balk
Organizations
- Beth Israel Deaconess Medical Center